BRPI0413233A - novos compostos - Google Patents

novos compostos

Info

Publication number
BRPI0413233A
BRPI0413233A BRPI0413233-5A BRPI0413233A BRPI0413233A BR PI0413233 A BRPI0413233 A BR PI0413233A BR PI0413233 A BRPI0413233 A BR PI0413233A BR PI0413233 A BRPI0413233 A BR PI0413233A
Authority
BR
Brazil
Prior art keywords
ring
optionally substituted
fused
unsaturated
heterocyclic ring
Prior art date
Application number
BRPI0413233-5A
Other languages
English (en)
Inventor
Sumihiro Nomura
Toshiaki Sakamoto
Kiichiro Ueta
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of BRPI0413233A publication Critical patent/BRPI0413233A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"NOVOS COMPOSTOS". A invenção descreve um composto de fórmula (I): onde a Anel A e o Anel B são (1) o Anel A é um anel heterocíclico, monocíclico, insaturado, opcionalmente substituído, e o Anel B é um anel heterocíclico, monocíclico, insaturado, opcionalmente substituído, um anel heterobicíclico fundido, insaturado, opcionalmente substituído, ou um anel benzeno opcionalmente substituído, (2) o Anel A é um anel benzeno opcionalmente substituído, e o Anel B é um anel heterocíclico, monocíclico, insaturado, opcionalmente substituído, um anel heterobicíclico fundido, insaturado, opcionalmente substituído, ou um anel benzeno opcionalmente substituído, ou (3) o Anel A é um anel heterobicíclico fundido, insaturado, opcionalmente substituído, onde o grupo -NR- e o grupo -CH~ 2~- estão ambos no mesmo anel do anel heterobicíclico fundido, insaturado, e o Anel B anel heterocíclico, monocíclico, insaturado opcionalmente substituído, um anel heterobicíclico fundido, insaturado, opcionalmente substituído, ou um anel benzeno opcionalmente substituído; e R é um átomo de hidrogênio, um grupo alquila inferior, um grupo alcanoila inferior ou um grupo alcoxicarbonila inferior ou um sal farmaceuticamente aceitável do mesmo ou um pró-medicamento do mesmo.
BRPI0413233-5A 2003-08-01 2004-07-30 novos compostos BRPI0413233A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49152303P 2003-08-01 2003-08-01
PCT/JP2004/011311 WO2005012321A1 (en) 2003-08-01 2004-07-30 Novel compounds

Publications (1)

Publication Number Publication Date
BRPI0413233A true BRPI0413233A (pt) 2006-10-03

Family

ID=34115512

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413233-5A BRPI0413233A (pt) 2003-08-01 2004-07-30 novos compostos

Country Status (18)

Country Link
US (1) US7521430B2 (pt)
EP (1) EP1654269B1 (pt)
JP (1) JP4717811B2 (pt)
KR (1) KR101101500B1 (pt)
CN (2) CN102060888A (pt)
AU (1) AU2004260760B2 (pt)
BR (1) BRPI0413233A (pt)
CA (1) CA2534022C (pt)
EA (1) EA011025B1 (pt)
ES (1) ES2527053T3 (pt)
IL (1) IL173051A (pt)
MX (1) MXPA06001273A (pt)
NO (1) NO333679B1 (pt)
NZ (1) NZ545305A (pt)
TW (1) TWI377209B (pt)
UA (5) UA86042C2 (pt)
WO (1) WO2005012321A1 (pt)
ZA (2) ZA200601686B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
MXPA06001274A (es) * 2003-08-01 2006-04-11 Tanabe Seiyaku Co Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
MY147375A (en) 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP5298025B2 (ja) * 2006-12-04 2013-09-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CN101801371B (zh) 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
BRPI0913129A2 (pt) 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
CN102159561A (zh) * 2008-09-19 2011-08-17 诺瓦提斯公司 糖苷衍生物及其用途
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101532412B1 (ko) 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
SG10201500258WA (en) * 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
EP2963048B1 (en) * 2013-02-26 2020-11-18 Mitsubishi Tanabe Pharma Corporation Method for producing alpha-halo-tetraacyl glucose
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法
ES2711804T3 (es) 2014-05-27 2019-05-07 Glenmark Pharmaceuticals Ltd Proceso para preparación de canagliflozina
CN104045673B (zh) * 2014-06-06 2017-01-18 安徽省食品药品检验研究院 双‑三氮唑缀合的假二糖衍生物及其制备方法
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN106188022A (zh) * 2015-04-30 2016-12-07 上海医药工业研究院 伊格列净的制备方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
MY210547A (en) 2017-11-30 2025-09-30 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
PT4188389T (pt) 2020-07-27 2025-10-07 Astrazeneca Ab Dapagliflozina para utilização em métodos de tratamento de doença renal crónica
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1075626B (de) * 1960-02-18 Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US7465712B2 (en) * 2000-03-17 2008-12-16 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
DE60122193T2 (de) * 2000-09-29 2007-07-05 Kissei Pharmaceutical Co., Ltd., Matsumoto Glucopyranosyloxybenzylbenzol derivate und medizinische zusammensetzungen, die diese verbindungen enthalten
AU2002223127A1 (en) * 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
SI1354888T1 (sl) 2000-12-28 2009-10-31 Kissei Pharmaceutical Glukopiranoziloksipirazolni derivati in njihova uporaba v zdravilih
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
AU2004260760B2 (en) 2009-08-13
UA85569C2 (ru) 2009-02-10
US20070060545A1 (en) 2007-03-15
NO333679B1 (no) 2013-08-05
IL173051A0 (en) 2006-06-11
TWI377209B (en) 2012-11-21
ZA200601686B (en) 2007-05-30
EP1654269A1 (en) 2006-05-10
EA011025B1 (ru) 2008-12-30
UA86042C2 (en) 2009-03-25
KR101101500B1 (ko) 2012-01-03
JP4717811B2 (ja) 2011-07-06
UA83377C2 (uk) 2008-07-10
NO20060219L (no) 2006-04-28
CN102060888A (zh) 2011-05-18
IL173051A (en) 2012-06-28
NZ545305A (en) 2008-11-28
UA87991C2 (en) 2009-09-10
ZA200603880B (en) 2010-01-27
AU2004260760A1 (en) 2005-02-10
US7521430B2 (en) 2009-04-21
EA200600348A1 (ru) 2006-08-25
KR20060132539A (ko) 2006-12-21
ES2527053T3 (es) 2015-01-20
CA2534022C (en) 2012-10-02
EP1654269B1 (en) 2014-10-15
TW200510440A (en) 2005-03-16
MXPA06001273A (es) 2006-04-11
WO2005012321A1 (en) 2005-02-10
CA2534022A1 (en) 2005-02-10
JP2007518682A (ja) 2007-07-12
UA86599C2 (en) 2009-05-12
CN1829728A (zh) 2006-09-06

Similar Documents

Publication Publication Date Title
TW200510440A (en) Novel compounds
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
BRPI0610312B8 (pt) dispositivo de assistência à caminhada
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
WO2009010789A3 (en) Pyrimidine derivatives 934
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
MY137761A (en) The use of n-arylhdrazine derivatives for combating non-crop pests
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
WO2005035537A3 (en) Substituted tricyclic heterocycles and their uses
AR045791A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.